Business Wire

CO-VANTAGE-DATA-CENTERS

13.12.2022 14:01:34 CET | Business Wire | Press release

Share
Vantage Data Centers Announces Second Campus in Johannesburg

Vantage Data Centers, a leading global provider of hyperscale data center campuses, announced today the construction of a second campus (JNB2) in Johannesburg, South Africa.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213005272/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

JNB11 facility on Vantage Data Centers' developing 80MW campus in Johannesburg, South Africa. The company is now developing a second campus 17 kilometers away. (Photo: Business Wire)

The JNB2 Isando campus is strategically located in Ekurhuleni, the greater Johannesburg Metropol’s trade and industry hub, and approximately 17 kilometers from Vantage’s growing JNB1 Midrand campus. JNB2 is sited near the OR Tambo International Airport and less than two kilometers from the NAPAfrica neutral Internet eXchange in a region that serves as the cloud on-ramp for a number of large technology companies.

“South Africa continues to be a cornerstone for Vantage’s EMEA growth outside of continental Europe,” said Antoine Boniface, president, Vantage Data Centers, EMEA. “Investing in a second campus is a testament to our commitment to the region and our customers who have business requirements to be in this high-demand market.”

The first building of the JNB2 campus will consist of a 20MW 355,000 square foot (33,000 square meters) two-story data center and will be operational in mid-2024. Vantage is repurposing a portion of an existing warehouse for the initial phase, reducing the embodied carbon of the development.

Sustainable Design

Many features of JNB2 are based on Vantage’s standardized campus blueprint, emphasizing sustainable construction practices. This includes offering renewable energy options through a recent Power Purchase Agreement with SolarAfrica, limiting carbon footprints, maintaining energy efficient operations with an industry-leading power usage effectiveness (PUE) and minimizing the use of water.

Power and Cooling

The first data center on the JNB2 campus will be cooled using a highly efficient, closed-loop chilled water system generated through air-cooled chillers. An integrated economizer capability will allow reduced compressor energy based on outside ambient temperature. This allows Vantage to take advantage of cooler seasonal temperatures to minimize resource usage. Customers will benefit from power provided by the Municipality of Ekurhuleni, combined with a dedicated on-site, high-voltage substation.

Security and Amenities

Campus security remains a priority for Vantage, and the company’s hallmark security measures include an on-site security operations center with 24x7x365 patrols, perimeter security, CCTV on all access points, and multi-level authentication and access controls for employees, customers and visitors.

This new data center will provide dedicated offices and workspaces, break areas, conference rooms, meeting spaces and secure storage areas.

JNB1 Expansion

On Vantage’s inaugural and award-winning 80MW campus in Midrand, South Africa, the company opened its first 16MW facility in July 2022, and continues expanding the development to meet customer demand. The next phase is under construction and is slated to be operational in early 2024.

For more information about Vantage’s global campus footprint, visit https://vantage-dc.com/data-center-locations/.

About Vantage Data Centers

Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.

For more information, visit www.vantage-dc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005272/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release

Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye